We are live on ! Find out more

CRDL

Cardiol Therapeutics

CRDL

Market cap $227M

1.94 USD

-0.12

5.83%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

1.97

+0.03

1.55%

1 day

-5.83%

5 days

3.19%

1 month

61.67%

3 months

51.56%

6 months

90.2%

Year to date

95.13%

1 year

77.98%

5 years

-46.99%

10 years

-18.83%

About: Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Employees: 18

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Zacks Investment Research

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?

Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial

Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application.

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT. Canaccord Genuity's 46th Annual Growth Conference When: Tuesday, August 11 at 9:00 a.m.

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association ("JAHA").

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m.

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated May 7, 2026.

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics' 2026 AGM When: June 24, 2026, at 4:30 p.m.

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m.

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA").

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

See News Rankings

Price charts implemented using Lightweight Charts™